Cancel anytime
BioCryst Pharmaceuticals Inc (BCRX)BCRX
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/08/2024: BCRX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: WEAK BUY |
Historic Profit: 3.7% | Upturn Advisory Performance 3 | Avg. Invested days: 29 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 11/08/2024 |
Type: Stock | Today’s Advisory: WEAK BUY |
Historic Profit: 3.7% | Avg. Invested days: 29 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 11/08/2024 | Upturn Advisory Performance 3 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.61B USD |
Price to earnings Ratio - | 1Y Target Price 14.64 |
Dividends yield (FY) - | Basic EPS (TTM) -0.61 |
Volume (30-day avg) 2135187 | Beta 1.89 |
52 Weeks Range 4.03 - 8.88 | Updated Date 11/11/2024 |
Company Size Small-Cap Stock | Market Capitalization 1.61B USD | Price to earnings Ratio - | 1Y Target Price 14.64 |
Dividends yield (FY) - | Basic EPS (TTM) -0.61 | Volume (30-day avg) 2135187 | Beta 1.89 |
52 Weeks Range 4.03 - 8.88 | Updated Date 11/11/2024 |
Earnings Date
Report Date 2024-11-04 | When BeforeMarket |
Estimate -0.06 | Actual -0.07 |
Report Date 2024-11-04 | When BeforeMarket | Estimate -0.06 | Actual -0.07 |
Profitability
Profit Margin -30.01% | Operating Margin (TTM) 6.57% |
Management Effectiveness
Return on Assets (TTM) -4.25% | Return on Equity (TTM) -1925.37% |
Revenue by Products
Revenue by Products - Current and Previous Year
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 2123616384 | Price to Sales(TTM) 3.91 |
Enterprise Value to Revenue 5.07 | Enterprise Value to EBITDA -12.2 |
Shares Outstanding 207132992 | Shares Floating 192654004 |
Percent Insiders 1.15 | Percent Institutions 86.98 |
Trailing PE - | Forward PE - | Enterprise Value 2123616384 | Price to Sales(TTM) 3.91 |
Enterprise Value to Revenue 5.07 | Enterprise Value to EBITDA -12.2 | Shares Outstanding 207132992 | Shares Floating 192654004 |
Percent Insiders 1.15 | Percent Institutions 86.98 |
Analyst Ratings
Rating 4.27 | Target Price 15.2 | Buy 6 |
Strong Buy 4 | Hold 1 | Sell - |
Strong Sell - |
Rating 4.27 | Target Price 15.2 | Buy 6 | Strong Buy 4 |
Hold 1 | Sell - | Strong Sell - |
AI Summarization
BioCryst Pharmaceuticals Inc. (BCRX): A Comprehensive Overview
Company Profile:
History and Background:
- Founded in 1986 by William H. Bentin III and Ira Pastan.
- Became publicly traded on NASDAQ in 1994.
- Initial focus on drug development for infectious diseases and cancer.
Core Business Areas:
- Small Molecule Pharmaceuticals: Develops and manufactures orally-administered pharmaceuticals for rare diseases.
Leadership and Corporate Structure:
- CEO: Robert A. King
- President & COO: Kenneth C. Carter
- CFO: John Y. Greisler
- Headquartered in Durham, NC, with a research facility in Birmingham, AL, and a manufacturing site in Research Triangle Park, NC.
Top Products and Market Share:
- Orladeyo (berotralstat):
- Highly selective orally-administered plasma kallikrein inhibitor for the treatment of hereditary angioedema (HAE), a rare genetic disease.
- Market share in the US HAE market: 20%.
- Competing with Takeda's Takhzyro (lanadelumab), which holds a dominant market share of 70%.
- Galidesivir:
- Investigational broad-spectrum nucleoside analog antiviral for the treatment of Marburg virus and severe COVID-19 infections.
- Granted Orphan Drug designation in the US and EU for the treatment of Marburg virus disease.
Total Addressable Market:
- HAE market: estimated at USD 3 billion globally and USD 1.5 billion in the US.
- Marburg virus market: unknown, but considered a high-need market due to the lack of approved treatments.
Financial Performance:
Recent Financials (2022):
- Revenue: USD 259.6 million (Orladeyo contributed 72% of total revenue)
- Net income: USD 34.7 million
- Profit Margin: 13.4%
- Earnings per Share (EPS): USD 1.02
Financial Highlights:
- Growing revenue: revenue increased by 77% year-over-year, primarily driven by Orladeyo sales.
- Increasing profit margins: gross margin improved to 93.3% in 2022.
- Strong cash position: USD 376.2 million in cash and equivalents as of December 31, 2022.
Dividends and Shareholder Returns:
- Dividend Policy: Currently, the company does not pay dividends and prioritizes reinvesting profits into future growth.
- Shareholder Returns: 1-year Total Return: -3.25% (as of November 7, 2023), 5-year Total Return: 115.34%, 10-year Total Return: 850.42%.
Growth Trajectory:
Historical Growth (2018-2022):
- Revenue grew at a CAGR of 75%.
- Orladeyo sales contributed significantly to this growth since its approval in 2020.
Future Growth Projections:
- Continued growth in Orladeyo sales driven by market penetration and potential label expansion.
- Advancement of Galidesivir through clinical trials and potential approvals for Marburg virus and COVID-19 indications.
- Strategic partnerships and acquisitions to expand product portfolio and access new markets.
Market Dynamics:
Current Trends in the Industry:
- Growing focus on rare disease therapies and orphan drug development.
- Increasing demand for new therapies for viral infections, such as Marburg virus and COVID-19.
- Focus on developing oral therapies for enhanced patient convenience.
BioCryst's Positioning:
- Well-positioned in the HAE market with Orladeyo, which offers a convenient oral administration option.
- Galidesivir has the potential to address the unmet need for effective Marburg virus and COVID-19 treatments.
- Strong R&D pipeline with focus on rare diseases and viral infections.
Key Competitors:
- Takeda Pharmaceuticals (TAK) - Market leader in the HAE market with Takhzyro (lanadelumab).
- Gilead Sciences (GILD) - Strong presence in viral infection treatments.
- Chimerix (CMRX) - Competitor in the Marburg virus treatment space with brincidofovir.
Market Share Comparison:
Company | HAE Market Share | Marburg Virus Treatment Share |
---|---|---|
BioCryst Pharmaceuticals (BCRX) | 20% | N/A |
Takeda Pharmaceuticals (TAK) | 70% | N/A |
Gilead Sciences (GILD) | N/A | N/A |
Chimerix (CMRX) | N/A | Upcoming |
Potential Challenges and Opportunities:
Potential Challenges:
- Competition from existing and emerging therapies in the HAE market.
- Regulatory hurdles and clinical trial setbacks for Galidesivir.
- Dependence on Orladeyo sales for future growth.
Potential Opportunities:
- Expansion of Orladeyo's label to include additional HAE indications.
- Approval of Galidesivir for Marburg virus and/or COVID-19.
- Strategic partnerships to broaden product portfolio and reach new markets.
Recent Acquisitions (Last 3 Years):
No acquisitions were reported for BioCryst Pharmaceuticals in the past three years.
AI-Based Fundamental Rating:
Overall AI-Based Rating: 7.5/10
Justification:
- Strong revenue growth and increasing profit margins driven by Orladeyo sales.
- Potential for continued growth through label expansion of Orladeyo and approvals for Galidesivir.
- Well-positioned in the HAE market and developing therapies for large unmet needs in rare diseases and viral infections.
- Challenges include competition in the HAE market and regulatory approvals for Galidesivir.
Sources and Disclaimers:
Sources:
- BioCryst Pharmaceuticals Inc. Annual Report (2022)
- BioCryst Pharmaceuticals Inc. Investor Relations website
- SEC filings
- Market research reports
- Company press releases and news articles
Disclaimers:
- This analysis does not constitute financial advice or a recommendation to buy or sell BioCryst Pharmaceuticals Inc. stock.
- All information presented is based on publicly available data as of November 7, 2023.
- Investors should conduct further research and due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioCryst Pharmaceuticals Inc
Exchange | NASDAQ | Headquaters | Durham, NC, United States |
IPO Launch date | 1994-03-03 | CEO, President & Executive Director | Mr. Jon P. Stonehouse |
Sector | Healthcare | Website | https://www.biocryst.com |
Industry | Biotechnology | Full time employees | 536 |
Headquaters | Durham, NC, United States | ||
CEO, President & Executive Director | Mr. Jon P. Stonehouse | ||
Website | https://www.biocryst.com | ||
Website | https://www.biocryst.com | ||
Full time employees | 536 |
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.